4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Now Rated "Moderate Buy" by Wall Street Brokerages

4D Molecular Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts’ consensus is “Moderate Buy”: Ten of 11 analysts rate FDMT a buy and one rates it a sell; the average 12-month price target is $30.22.
  • Shares opened at $12.25, within a 52-week range of $6.96–$16.93. The company reported quarterly EPS of -$1.04, slightly below estimates, while revenue of $3.78 million topped expectations.
  • Insiders have sold 123,790 shares worth about $1.66 million over the past three months; institutional investors and hedge funds own 99.27% of the stock.
  • Interested in 4D Molecular Therapeutics? Here are five stocks we like better.

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and ten have given a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $30.22.

FDMT has been the subject of several analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Thursday, October 15th. B. Riley Financial reissued a "buy" rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. HC Wainwright reaffirmed a "buy" rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, October 22nd. Cantor Fitzgerald raised 4D Molecular Therapeutics from a "neutral" rating to an "overweight" rating and set a $20.00 price target for the company in a research note on Monday, September 14th. Finally, Citigroup reiterated a "buy" rating on shares of 4D Molecular Therapeutics in a research note on Thursday, October 22nd.

Check Out Our Latest Stock Report on 4D Molecular Therapeutics

4D Molecular Therapeutics Stock Performance

FDMT opened at $12.25 on Friday. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05. 4D Molecular Therapeutics has a twelve month low of $6.96 and a twelve month high of $16.93. The firm has a market capitalization of $676.69 million, a PE ratio of -4.66 and a beta of 2.92. The firm's 50-day moving average price is $13.35 and its 200 day moving average price is $10.96.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). The firm had revenue of $3.78 million for the quarter, compared to analyst estimates of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. As a group, sell-side analysts expect that 4D Molecular Therapeutics will post -4.14 EPS for the current fiscal year.

Insider Activity

In related news, insider David Kirn sold 58,333 shares of the stock in a transaction on Monday, October 5th. The stock was sold at an average price of $12.92, for a total transaction of $753,662.36. Following the sale, the insider owned 709,153 shares of the company's stock, valued at $9,162,256.76. This trade represents a 7.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have sold 123,790 shares of company stock worth $1,655,545. 7.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. AlphaCore Capital LLC bought a new position in 4D Molecular Therapeutics during the third quarter worth $279,000. Allspring Global Investments Holdings LLC lifted its holdings in shares of 4D Molecular Therapeutics by 4.1% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 38,715 shares of the company's stock valued at $536,000 after buying an additional 1,515 shares during the period. StoneX Group Inc. acquired a new position in 4D Molecular Therapeutics during the 3rd quarter worth about $178,000. Alps Advisors Inc. lifted its holdings in 4D Molecular Therapeutics by 37.9% in the third quarter. Alps Advisors Inc. now owns 73,175 shares of the company's stock valued at $1,047,000 after acquiring an additional 20,119 shares during the period. Finally, Commonwealth Equity Services LLC lifted its holdings in shares of 4D Molecular Therapeutics by 7.4% during the 3rd quarter. Commonwealth Equity Services LLC now owns 30,677 shares of the company's stock valued at $439,000 after acquiring an additional 2,103 shares in the last quarter. Institutional investors and hedge funds own 99.27% of the company's stock.

About 4D Molecular Therapeutics

(Get Free Report)

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to design adeno-associated virus (AAV) vectors intended to deliver genetic medicines to specific tissues and organs.

Its pipeline has focused primarily on ophthalmology and pulmonology. Key investigational programs have included 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema, and 4D-710, an inhaled gene therapy designed to address the underlying cause of cystic fibrosis in patients who cannot benefit from existing CFTR modulator treatments.

Featured Stories

Analyst Recommendations for 4D Molecular Therapeutics (NASDAQ:FDMT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in 4D Molecular Therapeutics Right Now?

Before you consider 4D Molecular Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.

While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines